DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.

William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report), with a price ...

Denali Therapeutics showcases its BBB platform at J.P. Morgan Conference, highlighting DNL310's Hunter syndrome progress and plans for commercialization.

Jan. 15, 2025 — Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. ... New Innovative Local Treatment ...

In a report released today, Brendan Smith from TD Cowen maintained a Buy rating on Denali Therapeutics (DNLI – Research Report). The company’s ...

Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's ...

HC Wainwright raised their FY2028 earnings per share (EPS) estimates for Denali Therapeutics in a report issued on Tuesday, January 7th. HC Wainwright analyst A. Fein now expects that the company will ...

Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].